Robert Rosenson is a Cardiology physician affiliated with Mount Sinai Health System. OpenAlex indexes 36 publications with 1,403 citations (h-index 15); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1190 5th Ave
New York, NY 100296503
Telephone
212-427-1540Provider last certified this registry record 5 Dec 2023.
Clinical trials
- The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
Sponsor: Robert Rosenson
- Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
Sponsor: Icahn School of Medicine at Mount Sinai
- Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis
Sponsor: University of Michigan
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20256 payments
- Eli Lilly and CompanyProgram year20252 payments
- Novo Nordisk IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2019–2022 per NIH RePORTER. The latest:
- Use of High Density Lipoprotein Proteome in the Prediction of Cognitive Impairment and Alzheimer's Disease: (REGARDS)
Icahn School of Medicine at Mount Sinai
FY2022$540,619R01AG061186 - Use of High Density Lipoprotein Proteome in the Prediction of Cognitive Impairment and Alzheimer's Disease: (REGARDS)
Icahn School of Medicine at Mount Sinai
FY2021$532,144R01AG061186 - Use of High Density Lipoprotein Proteome in the Prediction of Cognitive Impairment and Alzheimer's Disease: (REGARDS)
Icahn School of Medicine at Mount Sinai
FY2020$686,541R01AG061186
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Yancovitz, MD
Mount Sinai Health System
Stephanie Blank, MD
Mount Sinai Health System
Robert Desnick, PhD, MD
Mount Sinai Health System
Mathew Williams, MD
Mount Sinai Health System
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”